← Back to Clinical Trials
Recruiting NCT06824480

NCT06824480 The Effect of Postpartum Debriefing on the Psychological Outcomes

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06824480
Status Recruiting
Phase
Sponsor Mersin University
Condition Well-Being, Psychological
Study Type INTERVENTIONAL
Enrollment 72 participants
Start Date 2024-02-01
Primary Completion 2025-02-07

Eligibility & Interventions

Sex Female only
Min Age 18 Years
Max Age 45 Years
Study Type INTERVENTIONAL
Interventions
debriefing groupcontrol group

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 72 participants in total. It began in 2024-02-01 with a primary completion date of 2025-02-07.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This study was planned to determine the effect of re-signification of birth in the early postpartum period on postpartum fear of childbirth, postpartum depression and birth trauma.

Eligibility Criteria

Inclusion Criteria: Women who volunteer to participate in the study, Whose mother tongue is Turkish, Who are between the ages of 18-45, Who are at least primary school graduates, Who are 37-42 weeks pregnant, Who are nulliparous, Who have a healthy pregnancy, Who do not have a psychological condition or psychiatric disorder, Who are monitored and cared for in the first 24 hours after birth at the Tarsus State Hospital Maternity Department, Who approve of the reinterpretation of birth application to be carried out by the researcher will be included in the sample. Exclusion Criteria: Those who did not volunteer to participate in the study, Those who gave birth before the 37th week of pregnancy, Those who were multiparous, Those who had abnormal medical conditions during pregnancy (placental disorder, preeclampsia, premature birth threat, etc.), Those whose native language is not Turkish, Those who have visual, speech and hearing impairments, Those who had an emergency cesarean section, Those who stayed in the hospital for less than 12 hours after birth, Those who received a psychiatric diagnosis during the postpartum period (except those diagnosed with postpartum depression and post-traumatic stress disorder related to birth), Those who could not be reached by phone during the follow-up of the study, Women who developed complications in the first 24 hours after birth and required intensive care, Those whose babies required neonatal intensive care during the postpartum period, Those who experienced another life event that traumatized the woman during the postpartum period (harassment, rape, earthquake, accident, loss of a loved one) etc.) Those who want to withdraw from the study at any stage of the study will not be included in the sample.

Contact & Investigator

Central Contact

gozde gokce ısbir professor dr. Gozde GOKCE ISBIR

✉ gozdegokce@gmail.com

📞 +905057782319

Frequently Asked Questions

Who can join the NCT06824480 clinical trial?

This trial is open to female participants only, aged 18 Years or older, up to 45 Years, studying Well-Being, Psychological. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06824480 currently recruiting?

Yes, NCT06824480 is actively recruiting participants. Contact the research team at gozdegokce@gmail.com for enrollment information.

Where is the NCT06824480 trial being conducted?

This trial is being conducted at Mersin, Turkey (Türkiye), Mersin, Turkey (Türkiye).

Who is sponsoring the NCT06824480 clinical trial?

NCT06824480 is sponsored by Mersin University. The trial plans to enroll 72 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology